Cargando…

Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27

BACKGROUND: Hypoxia can halt cell cycle progression of several cell types at the G1/S interface. The arrest needs to be overcome by cancer cells. We have previously shown that the hypoxia-inducible cellular oxygen sensor PHD3/EGLN3 enhances hypoxic cell cycle entry at the G1/S boundary. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Högel, Heidi, Miikkulainen, Petra, Bino, Lucia, Jaakkola, Panu M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520080/ https://www.ncbi.nlm.nih.gov/pubmed/26223520 http://dx.doi.org/10.1186/s12943-015-0410-5

Ejemplares similares

HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma
por: Miikkulainen, Petra, et al.
Publicado: (2017)

Prolyl Hydroxylase PHD3 Enhances the Hypoxic Survival and G1 to S Transition of Carcinoma Cells
por: Högel, Heidi, et al.
Publicado: (2011)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Transportable system enabling multiple irradiation studies under simultaneous hypoxia in vitro
por: Metsälä, Olli, et al.
Publicado: (2018)

Molecular Characterization and Response of Prolyl Hydroxylase Domain (PHD) Genes to Hypoxia Stress in Hypophthalmichthys molitrix
por: Li, Xiaohui, et al.
Publicado: (2022)

Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer
por: Rawluszko, Agnieszka A, et al.
Publicado: (2013)

Intermediary Metabolite Precursor Dimethyl-2-Ketoglutarate Stabilizes Hypoxia-Inducible Factor-1α by Inhibiting Prolyl-4-Hydroxylase PHD2
por: Hou, Peifeng, et al.
Publicado: (2014)

Prolyl hydroxylase 2 (PHD2) inhibition protects human renal epithelial cells and mice kidney from hypoxia injury
por: Fang, Yi, et al.
Publicado: (2016)

Hypoxia-inducible factor prolyl hydroxylase 1 (PHD1) deficiency promotes hepatic steatosis and liver-specific insulin resistance in mice
por: Thomas, Amandine, et al.
Publicado: (2016)

Hypoxia-inducible factor prolyl hydroxylase domain (PHD) inhibition after contusive spinal cord injury does not improve locomotor recovery
por: Wei, George Z., et al.
Publicado: (2021)

Prolyl-4-Hydroxylase 3 (PHD3) Expression Is Downregulated during Epithelial-to-Mesenchymal Transition
por: Place, Trenton L., et al.
Publicado: (2013)

Development of a colorimetric α-ketoglutarate detection assay for prolyl hydroxylase domain (PHD) proteins
por: Wong, Samantha J., et al.
Publicado: (2021)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer
por: Kozlova, Nina, et al.
Publicado: (2016)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

Caloric restriction counteracts age-dependent changes in prolyl-4-hydroxylase domain (PHD) 3 expression
por: Rohrbach, Susanne, et al.
Publicado: (2008)

Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins PHD1 and PHD2 but Not PHD3 Are Decreased in Primary Tumours and Correlate with Poor Prognosis of Patients with Surgically Resected Non-Small-Cell Lung Cancer
por: Koren, Ana, et al.
Publicado: (2021)

A computational evaluation of FDA medicines’ ability to inhibit hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for acute respiratory distress syndrome
por: Chandrasekaran, Jaikanth, et al.
Publicado: (2022)

Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
por: Savyuk, Maria, et al.
Publicado: (2020)

Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney transplant recipients
por: Ogata, Masatomo, et al.
Publicado: (2022)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

Gas tunnel engineering of prolyl hydroxylase reprograms hypoxia signaling in cells
por: Windsor, Peter, et al.
Publicado: (2023)

Intrabody against prolyl hydroxylase 2 promotes angiogenesis by stabilizing hypoxia-inducible factor-1α
por: Zhao, Liangzhong, et al.
Publicado: (2019)

Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility
por: Astuti, Dewi, et al.
Publicado: (2011)

Prolyl Hydroxylase Domain-Containing Protein 2 (Phd2) Regulates Chondrocyte Differentiation and Secondary Ossification in Mice
por: Cheng, Shaohong, et al.
Publicado: (2016)

mRNA overexpression of prolyl hydroxylase PHD3 is inversely related to nuclear grade in renal cell carcinoma
por: Kampantais, Spyridon, et al.
Publicado: (2020)

Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
por: Chan, Mun Chiang, et al.
Publicado: (2016)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Computational analysis of prolyl hydroxylase domain-containing protein 2 (PHD2) mutations promoting polycythemia insurgence in humans
por: Minervini, Giovanni, et al.
Publicado: (2016)

Lack of Skeletal Effects in Mice with Targeted Disruptionof Prolyl Hydroxylase Domain 1 (Phd1) Gene Expressed in Chondrocytes
por: Xing, Weirong, et al.
Publicado: (2022)

Exploring the natural products chemical space through a molecular search to discover potential inhibitors that target the hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD)
por: Sayaf, Abrar Mohammad, et al.
Publicado: (2023)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Decreased expression of prolyl hydroxylase 1 is associated with poor prognosis in colorectal cancers
por: Melling, Nathaniel, et al.
Publicado: (2023)

A Novel Prolyl Hydroxylase Inhibitor Protects Against Cell Death After Hypoxia
por: Kontani, Satoru, et al.
Publicado: (2013)

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications
por: Kim, So Yeon, et al.
Publicado: (2015)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases
por: Miao, Mengqiu, et al.
Publicado: (2022)

Structure–Activity Relationships and Transcriptomic Analysis of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors
por: Poloznikov, Andrey A., et al.
Publicado: (2022)

Cloning of the Human MORG1 Promoter: Differential Regulation by Hypoxia and Prolyl-Hydroxylase Inhibitors
por: Bondeva, Tzvetanka, et al.
Publicado: (2022)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
por: Chou, Yu-Hsiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uhm062pknmm3k5f1t3qai6v48u